ZA881053B - Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration - Google Patents

Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration

Info

Publication number
ZA881053B
ZA881053B ZA881053A ZA881053A ZA881053B ZA 881053 B ZA881053 B ZA 881053B ZA 881053 A ZA881053 A ZA 881053A ZA 881053 A ZA881053 A ZA 881053A ZA 881053 B ZA881053 B ZA 881053B
Authority
ZA
South Africa
Prior art keywords
compounds
prostaglandin
derivatives
pharmaceutical compositions
active agents
Prior art date
Application number
ZA881053A
Other languages
English (en)
Inventor
C. Froelich Juergen
Bippi Herbert
Original Assignee
C. Froelich Juergen
Bippi Herbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C. Froelich Juergen, Bippi Herbert filed Critical C. Froelich Juergen
Publication of ZA881053B publication Critical patent/ZA881053B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
ZA881053A 1987-02-16 1988-02-16 Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration ZA881053B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873704825 DE3704825A1 (de) 1987-02-16 1987-02-16 Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung

Publications (1)

Publication Number Publication Date
ZA881053B true ZA881053B (en) 1988-08-12

Family

ID=6321070

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA881053A ZA881053B (en) 1987-02-16 1988-02-16 Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration

Country Status (11)

Country Link
EP (1) EP0292643B1 (da)
JP (1) JPS63246331A (da)
AT (1) ATE80616T1 (da)
AU (2) AU623336B2 (da)
CA (1) CA1327359C (da)
DE (2) DE3704825A1 (da)
DK (1) DK173552B1 (da)
ES (1) ES2043696T3 (da)
GR (1) GR3005743T3 (da)
HU (1) HU199687B (da)
ZA (1) ZA881053B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2939569A (en) * 1957-10-16 1960-06-07 Gay W Roach Cotton weighing machine
US5530027A (en) * 1993-02-03 1996-06-25 Teijin Limited External skin treatment agent composition containing prostacyclins as active ingredient
WO1994017805A1 (en) * 1993-02-03 1994-08-18 Teijin Limited Dermatologic preparation composition containing isocarbacyclin as active ingredient
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2812193B1 (fr) * 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812191B1 (fr) * 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
CN1777429A (zh) * 2003-04-02 2006-05-24 尼克美制药控股有限公司 前列腺素组合物和其治疗血管痉挛的应用
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
US8940794B2 (en) 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3735005A (en) * 1970-08-19 1973-05-22 Alza Corp Method for preparing a viable platelet concentrate
US4205178A (en) * 1976-12-30 1980-05-27 The Upjohn Company 6-Keto prostaglandin E-type compounds
AU511711B2 (en) * 1976-12-30 1980-09-04 Upjohn Company, The 6-Oxo and 5, 6-Dihalo prostaglandin analogues
JPS6022710B2 (ja) * 1977-09-16 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
US4707495A (en) * 1985-10-28 1987-11-17 Ortho Pharmaceutical Peptic ulcer treatment method

Also Published As

Publication number Publication date
DE3874610D1 (da) 1992-10-22
DK77588D0 (da) 1988-02-15
GR3005743T3 (da) 1993-06-07
DK173552B1 (da) 2001-02-26
DK77588A (da) 1988-08-17
HU199687B (en) 1990-03-28
AU1518492A (en) 1992-06-25
AU649130B2 (en) 1994-05-12
ATE80616T1 (de) 1992-10-15
AU1176688A (en) 1988-08-18
JPS63246331A (ja) 1988-10-13
AU623336B2 (en) 1992-05-14
EP0292643B1 (de) 1992-09-16
CA1327359C (en) 1994-03-01
HUT46224A (en) 1988-10-28
EP0292643A1 (de) 1988-11-30
ES2043696T3 (es) 1994-01-01
DE3704825A1 (de) 1988-08-25

Similar Documents

Publication Publication Date Title
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
HU892559D0 (en) Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient
IE894048L (en) New therapeutically active compound and a process for its¹preparation
EP0279149A3 (en) Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same
MY102038A (en) 4-substituted androstendione derivatives and process for their preparation
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
TW234691B (da)
IL108071A0 (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines their preparation and pharmaceutical compositions containing them
ZA881053B (en) Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration
EP0620004A4 (en) MEDICAL COMPOSITION.
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
CS734389A3 (en) 4-fluoro-2-//(4-methoxy-2-pyridyl)methyl/sulfinyl/ -1h - benzimidazole, process for its production and a pharmaceutical comprising said compound as an active component
AU2617288A (en) Pharmaceutical formulations for transdermal administration
IE56229B1 (en) 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them
ES8203349A1 (es) Un procedimiento para la preparacion de 1,2-bis(nicotinami- do) propano
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
SE7708622L (sv) 2-bensyl-perhydroazepiner, sett for framstellning derav och lekemedel, innehallande dem
MX9305578A (es) Adsorbato a base de una mezcla de sustancias auxiliares y un principio activo no solido para la produccion de preparados medicamentosos.
DE3372772D1 (en) Quinazolinone derivatives, process for their preparation and their use in medicaments
GB1465771A (en) Pharmaceutical composition and use thereofd
JO1531B1 (en) New near-compounds
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)
FR2567755B1 (fr) Nouveau medicament anti-tumoral contenant comme ingredient actif le triacetoxy-1,8,9 anthracene